Skip to content

US · FDMT · BIOTECHNOLOGY

4D Molecular Therapeutics, Inc. (FDMT) intrinsic value and stock valuation

$10.23as of 2026-11-21 · Mkt cap 537.4M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

4D Molecular Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values FDMT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FDMT’s statements →

4D Molecular Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology EmeryVille, CA 94608 4dmoleculartherapeutics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$85.2M+44.3% 5y CAGRd
20172025
Net income
-$-140.11M
20172025
Free cash flow
-$-109.08M
20172025
Total equity
$505.7M+14.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$85.2M$40K$20.7M$3.13M$18M
Operating income-$-159.55M-$-187.84M-$-112.87M-$-110.03M-$-71.33M
Net income-$-140.11M-$-160.87M-$-100.84M-$-107.49M-$-71.32M
EPSd-$-2.42M-$-2.98M-$-2.58M-$-3.32M-$-2.57M
Operating cash flow-$-109.08M-$-134.59M-$-75.79M-$-86.69M-$-69.13M
Capital expenditure-$-540K-$-3.79M-$-2.77M-$-11.54M-$-9.11M
Free cash flow-$-109.08M-$-138.37M-$-78.56M-$-98.22M-$-78.24M
Total assets$566.7M$560.4M$339.9M$261.9M$353.5M
Total debt$21.4M$24.6M$14.7M$16.1M$16.5M
Net debt-$-38.83M-$-124.73M-$-234.44M-$-36.23M-$-136.55M
Total equity$505.7M$510.6M$307.8M$231.3M$319.1M
Cash and short-term investments$402.7M$424.9M$288.2M$213.6M$247.8M
Income statement
20252024202320222021
Revenue$85.2M$40K$20.7M$3.13M$18M
Cost of revenue$7.62M$141.3M$97.1M$80.3M$61.4M
Gross profit$77.6M-$-141.26M-$-76.37M-$-77.12M-$-43.32M
Research and development expenses$195.7M$141.3M$97.1M$80.3M$61.4M
Selling, general and administrative expenses$49.1M$46.6M$36.5M$32.9M$28M
Other expenses-$-7.62M-$-141.3M-$-97.1M-$-80.25M-$-61.36M
Operating expenses$237.1M$46.6M$36.5M$32.9M$28M
Cost and expenses$244.8M$187.9M$133.6M$113.2M$89.4M
Interest income$19.5M$27.1M$12.2M$2.57M$140K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$7.62M$6.71M$4.2M$2.4M$1.52M
Ebitda-$-132.48M-$-154.16M-$-96.63M-$-105.09M-$-69.79M
Operating income-$-159.55M-$-187.84M-$-112.87M-$-110.03M-$-71.33M
Total other income/expenses, net$19.4M$27M$12M$2.54M$20K
Income before tax-$-140.11M-$-160.87M-$-100.84M-$-107.49M-$-71.32M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-140.11M-$-160.87M-$-100.84M-$-107.49M-$-71.32M
Weighted average shares outstanding$57.9M$53.9M$39.1M$32.4M$27.7M
Weighted average diluted shares outstanding$57.9M$53.9M$39.1M$32.4M$27.7M
Balance sheet
20252024202320222021
Cash and short-term investments$402.7M$424.9M$288.2M$213.6M$247.8M
Net receivables$0.00$0.00$0.00$700K$50K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$413.1M$434.9M$296.6M$220.5M$256.3M
Property, plant and equipment, net$33M$40.6M$31.7M$35.4M$29M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$111.4M$80.6M$11M$4.91M$67.7M
Total non-current assets$153.6M$125.5M$43.3M$41.3M$97.2M
Total assets$566.7M$560.4M$339.9M$261.9M$353.5M
Accounts payable$11.2M$4.39M$3.52M$3.32M$4.76M
Short-term debt$5.59M$5.64M$3.15M$5.31M$1.23M
Deferred revenue$360K$260K$270K$880K$2.6M
Total current liabilities$44M$29.2M$19M$15.7M$16.3M
Long-term debt$15.8M$19M$11.5M$13.5M$15.2M
Deferred revenue, non-current$740K$1.06M$970K$1.08M$2.49M
Total non-current liabilities$17.1M$20.6M$13.1M$14.8M$18M
Capital lease obligations$21.4M$24.6M$14.7M$16.1M$16.5M
Total liabilities$61.1M$49.8M$32.1M$30.5M$34.4M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-716.3M-$-576.2M-$-415.33M-$-314.49M-$-207M
Accumulated other comprehensive income (loss)$730K$230K$20K-$-1.2M-$-420K
Total equity$505.7M$510.6M$307.8M$231.3M$319.1M
Total investments$453.8M$356.1M$50.1M$166.1M$162.4M
Total debt$21.4M$24.6M$14.7M$16.1M$16.5M
Net debt-$-38.83M-$-124.73M-$-234.44M-$-36.23M-$-136.55M
Cash flow statement
20252024202320222021
Net income-$-140.11M-$-160.87M-$-100.84M-$-107.49M-$-71.32M
Depreciation and amortization$7.62M$6.71M$5.75M$3.88M$3.02M
Stock-based compensation$22M$26.1M$19.7M$17.1M$13.8M
Change in working capital$6.17M$540K$630K-$-1.34M-$-15.53M
Accounts receivable$0.00$0.00$0.00$50K$1.44M
Inventory$0.00$0.00$0.00$0.00-$-4.54M
Accounts payable$6.77M$870K$900K-$-1.64M$2.29M
Net cash provided by operating activities-$-109.08M-$-134.59M-$-75.79M-$-86.69M-$-69.13M
Investments in property, plant and equipment-$-540K-$-3.79M-$-2.77M-$-11.54M-$-9.11M
Acquisitions, net$0.00$0.00$0.00$0.00$9.11M
Net cash used for investing activities-$-92.97M-$-302.44M$115.7M-$-17.05M-$-172.68M
Common stock issued$113M$331.4M$148.3M$3.08M$114.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$113M$337.3M$156.8M$3.08M$118.1M
Net change in cash-$-89.09M-$-99.77M$196.8M-$-100.65M-$-123.72M
Cash at end of period$60.2M$149.3M$249.1M$52.4M$153M
Operating cash flow-$-109.08M-$-134.59M-$-75.79M-$-86.69M-$-69.13M
Capital expenditure-$-540K-$-3.79M-$-2.77M-$-11.54M-$-9.11M
Free cash flow-$-109.08M-$-138.37M-$-78.56M-$-98.22M-$-78.24M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 4D Molecular Therapeutics, Inc.

        4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

        CEO
        David H. Kirn
        Employees
        196
        Beta
        2.69

        Explore

        Frequently asked questions

        What is the intrinsic value of 4D Molecular Therapeutics, Inc. (FDMT)?

        InvestorsCraft does not currently publish an intrinsic value for FDMT. How the IC value is calculated.

        Is FDMT undervalued?

        InvestorsCraft does not publish an undervaluation signal for FDMT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.